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Abstract
Background: The choice of any radiotherapy treatment plan is usually made after the evaluation of a few
preliminary isodose distributions obtained from different beam configurations. Despite considerable advances in
planning techniques, such final decision remains a challenging task that would greatly benefit from efficient and
reliable assessment tools.
Methods: For any dosimetric plan considered, data on dose-volume histograms supplied by treatment planning
systems are used to provide estimates on planning target coverage as well as on sparing of organs at risk and the
remaining healthy tissue. These partial metrics are then combined into a dose distribution index (DDI), which provides
a unified, easy-to-read score for each competing radiotherapy plan. To assess the performance of the proposed
scoring system, DDI figures for fifty brain cancer patients were retrospectively evaluated. Patients were divided in
three groups depending on tumor location and malignancy. For each patient, three tentative plans were designed
and recorded during planning, one of which was eventually selected for treatment. We thus were able to compare
the plans with better DDI scores and those actually delivered.
Results: When planning target coverage and organs at risk sparing are considered as equally important, the tentative
plan with the highest DDI score is shown to coincide with that actually delivered in 32 of the 50 patients considered.
In 15 (respectively 3) of the remaining 18 cases, the plan with highest DDI value still coincides with that actually
selected, provided that organs at risk sparing is given higher priority (respectively, lower priority) than target coverage.
Conclusions: DDI provides a straightforward and non-subjective tool for dosimetric comparison of tentative
radiotherapy plans. In particular, DDI readily quantifies differences among competing plans with similar-looking
dose-volume histograms and can be easily implemented for any tumor type and localization, irrespective of the
planning system and irradiation technique considered. Moreover, DDI permits to estimate the dosimetry impact of
different priorities being assigned to sparing of organs at risk or to better target coverage.
Keywords: Decision-support system, Plan evaluation, Radiation dose distribution index, Dose-volume histograms,
Radiotherapy treatment planning
Background
A radiotherapy treatment plan is expected to uniformly
irradiate a selected planning target volume (PTV), while
at the same timeminimizing radiation-induced damage to
organs at risk (OARs) and the remaining volume at risk
(RVR) [1–3]. To that end, a prescription dose (Dp) to be
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delivered at the PTV should be defined, whereas radia-
tion doses at OARs and RVRs should be kept as low as
possible. To address that issue, computerized treatment
planning systems (TPS) are used to simulate a number
of tentative plans. For any such plan, the TPS provides
dose-volume histograms (DVHs) for the PTV and each
OAR delineated, as well as the isodose curves over the
whole treatment domain. The choice of the treatment plan
is then usually made, regardless of further physical and
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radiobiological considerations, mainly by inspection of
the DVHs and isodose curves obtained for each tentative
plan considered.
It is widely accepted that the decision-making process
just recalled is highly subjective. Actually, considerable
skills are required to pick up the most suitable tenta-
tive plan from a mere inspection of the DVHs and iso-
dose curves of competing plans, since these may look
quite similar to the naked eye. During the last decades,
a number of approaches have been proposed to improve
the choice of treatment plans. However, and in spite of
the large efforts made so far, no widely accepted quan-
titative decision-support tool seems to be currently in
clinical use [3, 4]. A standard approach towards deriving
such decision-support tools has consisted in proposing
physical-based quantitative metrics. Such metrics assign
a score to a dosimetric plan according to its compliance
with specified physical criteria [3]. Paramount among
them, the conventionally used homogeneity index (HI)
is defined as the ratio between the maximum radiation
dose in the PTV and the prescription dose [5, 6]. In
addition, alternative indices of dose homogeneity on the
target have been proposed [7–10], which however fail
often to accurately account for dose homogeneity within
the PTV [7, 11]. On the other hand, a conformity index
(CI) was first proposed in the Radiation Therapy Oncol-
ogy Group (RTOG) radiosurgery guidelines [5], where it
was defined as the ratio of the prescription isodose vol-
ume to the target volume. However, CI can yield false
positives in extreme cases of nonconcordance between
the target volume and isodose curves [6, 12]. Other con-
formity indices have been proposed [13–18], but prac-
tical limitations to their use have been pointed out in
ICRU reports [1–3]. A major drawback of most of such
indices is that they do not consider the overall dosimet-
ric information provided by DVHs. As a matter of fact,
a consensus has been built to consider DVHs as key
indicators of the compliance with clinical requirements,
and for that reason DVHs are routinely provided by the
TPS.
The previous figures of merit provide a measure of
target coverage and conformity only, without assessing
organs at risk and healthy tissue sparing. This is a seri-
ous drawback, since normal tissue morbidity often rep-
resents the main limiting factor to radiation delivery and
treatment outcomes [19, 20]. For that reason, several
volume-based indices have been proposed to estimate
such effects. These include, the healthy tissue over-
dosage factor (HTOF) [6], healthy tissue conformity index
(HTCI) [6, 15] and critical organ-scoring index (COSI)
[21]. Moreover, dose conformality at the PTV and OARs
has also been simultaneously quantified [6, 22–24]. How-
ever, questions have been raised about the suitability of
such indices to account for cold and hot spots (regions
receiving particularly low or high radiation doses) in the
PTV and OARs respectively [6, 7, 24].
It follows from our previous remarks that a single assess-
ment index, accounting for a particular clinical aspect
during planning, may not be suitable to compare ten-
tative plans since it might ignore other key dosimetric
issues. For this reason, indices have been proposed that
provide combined scores for several treatment require-
ments. For instance, an overall quality factor (QF) and
a unified dosimetry index (UDI) have been defined as
weighted combinations of some of the indices mentioned
before [25, 26]. However, the difficulty in interpret-
ing the overall score thus obtained sets serious lim-
itations to their practical use. Moreover, the figures
of merit proposed often depend on many parameters
[21, 24, 27], provide ambiguous scoring due to averaging
effects [23, 25] and are not easy to implement in clinical
routine [26, 28].
The indices recalled above are purely physical quan-
tities based on dose-volume constraints. Radiobiological
indices, such as tumor control probability (TCP) and nor-
mal tissue complication probability (NTCP), aim instead
at estimating the effects of radiation on pathological
and healthy tissues resulting from a given dose distribu-
tion. A large range of TCP [29–31] and NTCP [32–36]
models have been reported, but recommendations in the
ICRU reports suggest that they should be used with
caution in clinical practice [1–3]. In particular, a major
limitation to their use stems from the difficulty to esti-
mate tissue-dependent parameter values to character-
ize the radiobiological response of tumors and organs
involved. In many situations of clinical interest, such
parameters have only been estimated in vitro or remain
unknown.
Methods
Dose distribution index (DDI)
A dosimetric comparison system, the dose distribution
index (DDI), is proposed to assist in the choice of radio-
therapy treatment plans for any given cancer patient. DDI
simultaneously takes into account key dosimetric issues
as dose coverage, conformity and homogeneity over the
PTV, as well as sparing of OARs and the RVR. Only stan-
dard information provided by the TPS, namely the DVHs
and the prescription dose on the PTV, are required to
grade and evaluate tentative plans. Moreover, one can
readily estimate the separate impact on the PTV coverage
and sparing of OARs and RVRs of any such modification,
and thus use this information as a guidance to improve a
tentative treatment plan.
The proposed decision-support system is defined as a
weighted sum of three components, which quantify the
overall quality of a dosimetric plan. The first of those
components assesses the dose coverage, conformity and
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homogeneity on the planning target, and it is defined as
follows:
IT =
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where PTV is the planning target volume, Dp is the pre-
scription dose on the PTV, Dm is the maximum dose
received at least by 100% of the PTV, DM is the maxi-
mum dose in the PTV and VT (D) represents the DVH
curve corresponding to the target. More precisely, this
index computes the ratio between the areas under the
DVH curve for any tentative plan considered and that
corresponding to an ideal plan of constant Dp uniformly
delivered on the PTV, see Fig. 1(a). The ratio (Dm/DM)
is included in (1) to account for dose homogeneity in
the PTV. Alternatively, and depending on clinical require-
ments, this ratio might be taken as (D95/D5), where D5
and D95 are the dose received by the 5 and 95% of the
PTV respectively [7, 11]. Notice that as far as the PTV is
considered, an ideal plan ensuring perfect dose coverage
would yield a score IT = 1.
We argue in a similar way to estimate the merit of a
tentative treatment plan with respect to sparing of OARs
and the RVR. In this case, a good plan would make
close to zero the area under the DVH corresponding to
such critical structures, see Fig. 1(b). The contributions to
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Fig. 1 Schematic representation of dose-volume histograms. a A DVH
corresponding to a PTV and b an OAR or the RVR. The factors involved
in the formulation of IT , IO and IR are also indicated, see (1), (2) and (3)
respectively
the DDI of OARs and RVR components are respectively
formulated as follows:
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where DM is the maximum dose in each structure
involved, N is the number of OARs considered, OARV is
the volume of a given OAR, VO(D) and VR(D) represent
the DVH curves of a given OAR and the RVR respectively.
The ratio (DM/Dp) is included to weight the deviation of
the maximum dose received by OARs and the RVR from
the prescription dose Dp on the PTV, the latter remaining
constant for each competing plan considered for a same
patient. The nonnegative weighting factors wOi ≤ 1.0 in
(2) account for the relative clinical importance assigned
to each OAR considered. In what concerns OARs and the
RVR, an ideal plan would yield IO = IR = 1, which would
result in no irradiation at all on such critical volumes.
The DDI decision-support system is given by:
DDI = 13 (wTIT + wOIO + wRIR) , (4)
where wT , wO and wR are nonnegative weighting param-
eters, each ranging between zero and one, that make
precise the relative clinical priority assigned to the indices
(1), (2) and (3) during the treatment planning process.
These parameters allow to account for the relative impor-
tance assigned to target coverage and organs at risk spar-
ing, from highly important (weight factor equal to 1)
to less important (weight factor close to 0). In partic-
ular, if weights are selected equal 1 then all the struc-
tures involved are considered as equally important. In
that manner, the DDI encodes the contributions from
all three components into a unified score as defined by
equation (4). Notice that an ideal plan would give DDI =
1, which corresponds to uniform delivery of the Dp to the
PTV and no irradiation at all in OARs and the RVR. The
previous formulation can be easily extended to include
several PTVs, similarly to what has been done for OARs
in (2). In fact, this may be the case when a heterogeneous
planning target is considered, and non-homogeneous
radiation doses are prescribed [10, 28, 37]. For conve-
nience of the reader, we summarize in Table 1 the notation
used in the formulation of this decision-support system.
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Table 1 Description of the notation used in the formulation of
the DDI decision-support system
Symbol Description
Dp Prescription radiation dose on the PTV
DM Maximum dose in each structure delineated
Dm Maximum dose received at least by 100% of the PTV
N Number of OARs considered
PTV Planning target volume
OARVi Volume of the ith OAR considered
RVR Remaining volume at risk
VT (D) DVH curve of the PTV
VOi(D) DVH curve of the ith OAR considered
VR(D) DVH curve of the RVR
wT Weight associated to IT
wO Weight associated to IO
wOi Weight associated to the ith OAR considered
wR Weight associated to IR
To illustrate how the DDI would work in clinical prac-
tice, we have performed a retrospective study over fifty
brain cancer patients already treated at Hospital Univer-
sitario Puerta de Hierro in Madrid (HUPH). For each
patient, three tentative plans were designed with the same
TPS during the planning process. Out of the three com-
peting plans considered, one was the selected by clinicians
and delivered to the patient. We have then compared in
each case the applied treatment plan with the tentative
plan achieving the highest DDI score.
Patients’ characteristics
Fifty brain cancer patients randomly selected and pre-
viously treated by external beam radiotherapy at HUPH
between the years 2012 and 2014 were considered for the
present study. In particular, patients with brain tumors
were selected due the large amount of OARs involved,
and the consequent difficulty of global evaluation of
PTV coverage and OARs sparing. The patients were
divided in three different groups, based on tumor loca-
tion and malignancy, as follows: (i) 25 patients with
centrally located benign tumors (13 Meningiomas, 6
Pituitary Adenomas, 5 Acoustic Neuromas and 1 Facial
Nerve Neuroma) representing 50% of the sample; (ii)
10 patients with centrally located malignant tumors (4
Malignant Craniopharyngiomas, 2 Cavum Carcinomas,
3 Chondrosarcomas and 1 Clear Cell Carcinoma (CCC)
of the Base of the Tongue) making up for 20% of the
total, and (iii) 15 patients with peripheral benign and
malignant tumors (12 Brain Metastasis, 2 Astrocytomas
and 1Meningioma) which correspond to 30% of the cases
considered.
Volume definitions
PTVs, OARs and RVRs were defined as recommended by
ICRU reports [1–3]. The gross tumour volume (GTV) was
delineated on all relevant slices of a planning CT scan.
The margins were then expanded isotropically to allow
for microscopic invasion, thus giving raise to the clini-
cal target volume (CTV). This last is further enlarged to
allow for organ motion and set-up error. The resulting
structure of interest is then defined as the planning tar-
get volume (PTV). The organs selected as OARs including
the Brainstem, Eyes, Crystalline Lens, Lacrimal Glands,
Retinas, Optic Chiasm, Hypothalamus, Cochleas, Spinal
Cord, Parotid Glands, Pituitary Gland, Optic Nerves,
Optic Tracts and Cranial Nerves (Trigeminal, Facial and
Vestibulocochlear Nerves) were contoured on the relevant
transverse CT slices of the planning system.
Treatment planning
For each patient, three different tentative plans using
three-dimensional conformal radiation therapy (3D-CRT)
or sliding windows intensity-modulated radiation therapy
(IMRT) were simulated. The dose-volume planning pre-
scription on the target required that at least 95% of the
PTV had to receive no less than 95% of the prescription
dose. This last was established at 50.4 Gy in 28 daily
fractions (5 days a week) of 1.8 Gy for conventional frac-
tionation protocols (in twenty-nine out of fifty patients,
58% of total), and between 12Gy–18Gy in a single session
for stereotactic radiosurgery (in the remaining twenty-
one patients, 42% of total). The dose planification system
was an iPLAN RT Dose 4.1.1 (BrainLAB AG, Germany).
Sets of three alternative treatment plans, with the same
radiotherapy technique, structures of interest and clinical
requirements, were prepared for each patient. Out of the
three tentative plans considered, one was selected and then
delivered to the patient. For all tentative plans the DVHs co
rresponding to each volume delineated were extracted from
the treatment planning system for computation of the DDI.
Results
In Table 2 the resulting mean IT , IO, IR and DDI scores, as
well as standard deviations for the overall set of tentative
plans are provided. Weighting factors in components (2)
and (4) were set equal to one, so that the PTV coverage
and sparing of OARs and RVRs are considered as equally
important. The lowest and highest DDI scores, corre-
sponding to the minimum and maximum deviations from
an ideal dosimetric plan, were 0.70 and 0.98 respectively.
A comparison of mean IT , IO, IR and DDI scores, as well as
standard deviations for all tentative plans corresponding
to patients with centrally and peripherally located tumors
is also shown in Table 2. From the results displayed there,
we observe that tentative plans for peripheral targets are
in average closer to an ideal dosimetric plan than those for
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Table 2 Scoring results corresponding to all tentative plans for the fifty brain cancer patients considered and differences between
centrally and peripherally located tumors
IT IO IR DDI
Mean Std Mean Std Mean Std Mean Std
T 0.87 0.12 0.85 0.11 0.93 0.04 0.88 0.09
CL 0.86 0.11 0.83 0.10 0.94 0.03 0.87 0.08
PL 0.93 0.07 0.97 0.02 0.96 0.02 0.95 0.04
Mean IT , IO , IR and DDI scores, as well as standard deviations are represented for all tentative plans (T) and centrally and peripherally located tumors (labelled as CL and PL
respectively)
centrally located targets with respect to PTV coverage and
sparing of OARs and RVRs. Figure 2 shows the DDI scores
for all tentative plans for each group of patients consid-
ered, as well as the corresponding means and standard
deviations. The small differences observed on theDDI val-
ues between competing plans in some patients are nearly
imperceptible to the naked eye and thus difficult to detect
and quantify. However, the DDI was able to significantly
discriminate between similar-looking DVHs when scoring
the corresponding tentative plans.
Concerning the degree of coincidence between the
applied treatment plan (ATP) and the tentative plan
(DDIP) achieving the highest DDI score, we separately
analyzed each group of patients classified by their tumor
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
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1.00
Patients
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Fig. 2 Plots of the DDI scores for each set of three tentative plans corresponding to the fifty brain cancer patients considered. Applied treatment
plan in red, and discarded tentative plans in green and purple. a 25 centrally located benign tumors. b 15 peripherally located benign and malignant
tumors. c 10 centrally located malignant tumors. Mean DDI scores (black solid lines) and standard deviations (blue solid lines) are also represented
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location and malignancy. In the cases of (i) centrally
located benign tumors, (ii) centrally located malignant
tumors and (iii) peripherally located benign andmalignant
tumors, we obtained that ATP andDDIP agree in 17 out of
the 25, 6 out of the 10, and 9 out of the 15 patients respec-
tively, see Fig. 2. Altogether, this results in an agreement
between ATP and DDIP for 32 out of the 50 patients in
this study under the assumption that PTV coverage and
sparing of OARs and the RVR are considered as equally
important.
To shed some light on the clinical choices made for the
patients where ATP and DDIP did not coincide, we sep-
arately analyzed the DDI components for the planning
target and critical structures in such cases. Figure 3 shows
a comparison of the mean IT and (IO + IR) /2 scores,
which respectively estimate the quality of PTV coverage
and critical structures sparing, for ATPs and the remain-
ing competing plans for patients where ATP and DDIP did
not coincide. We observe that, although the APTs were
not in average the choices providing better PTV cover-
age, they yielded lower irradiation of critical structures.
More precisely, in 15 out of the 18 cases of no coincidence
(IO + IR) /2 was higher in the APTs compared to other
competing plans, while IT was higher in the ATPs of the
remaining 3 patients.
To gain further insight in one of the discrepancy cases,
we selected a patient diagnosed with a centrally located
Meningioma, where the ATP and DDIP did not coincide.
Figure 4 shows the DVHs for the PTV and nearby OARs
corresponding to the three different tentative plans pre-
pared for that patient. OARs receiving low radiation doses
Fig. 3 Comparison of scoring results for the cases where ATP and
DDIP did not coincide. The mean IT and joint IO and IR defined as
(IO + IR)/2 scores and standard deviations are provided for the ATPs
(label AP) and remaining tentative plans (label RP)
as Eyes, Lacrimal Glands, Crystalline Lens and Retinas
have not been represented for visualization simplicity, but
all of them were considered in the calculation of the DDI
scores. A quick glance at Fig. 4 reveals that in all tentative
plans the target coverage is significantly high. However,
what is unclear is which plan best provides target coverage
and OARs sparing. In fact, when DVHs for all competing
plans are superposed as shown in Fig. 4, the high num-
ber of OARs involved makes difficult to select the most
suitable plan by mere inspection.
In Table 3 the IT , IO, IR and DDI scores for such ten-
tative plans are provided. We see that if PTV coverage is
given maximum priority, the best choice corresponds to
Plan 3, followed by Plans 2 and respectively 1. On the con-
trary, when lowering radiation doses on OARs and the
RVR are selected as the primary clinical goal, the most
suitable choice would be Plan 1, followed by Plans 2 and
3 respectively. Thus, consideration of partial DDI scores
reveals that increasing (respectively decreasing) the target
coverage was detrimental (respectively favorable) to spar-
ing of OARs and the RVR. Although based on the DDI
scores the Plan 2 provided the best balance between tar-
get coverage and sparing of critical structures, the Plan 1
was actually selected for treatment. This is consistent with
highest priority having been assigned to sparing of OARs
and the RVR at that time. For instance, a choice of rela-
tive weighting factors in (4) as wT = 0.5, wO = 1.0 and
wR = 1.0 would have suggested that choice.
Discussion
The availability of commercial TPS allows radiophysicists
and radiation oncologists to virtually explore different
tentative plans, and to perform successive modifications
of a starting plan, for each radiotherapy patient. How-
ever, to this day the choice of treatment plans is mostly
made by side-by-side comparison of DVHs and isodose
curves for each tentative plan considered. Since differ-
ences between them are usually small, any selection made
by inspection, as it is generally the case, may not be easy
to justify on clinical terms. Therefore, the development of
clinically based quantitative scoring indices could be quite
useful as decision-support tools to assist in making clin-
ical choices. For that purpose, several indices for scoring
dosimetric plans have been proposed and shortly recalled
at the ‘Background’ Section.
Bearing these facts in mind, we have introduced here a
decision-support system, termed dose distribution index
(DDI), to compare different tentative plans and to estimate
the consequences of modifications on any treatment plan
under consideration. The DDI makes use of the overall
dosimetric information provided by the DVHs to simulta-
neously evaluate the target coverage and sparing of critical
structures. Moreover, this evaluation tool can be easily
extended to include several PTVs, as well as multiple
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Fig. 4 DVHs corresponding to the PTV (a), OARs (b) and RVR (c) for the three tentative plans of a patient diagnosed with a centrally located
Meningioma. The Dp on the PTV was set equal to 50.4 Gy in 28 daily fractions (5 days per week) of 1.8 Gy
dose coverage objectives on heterogeneous tumors. In
our view, such features represent a comparative advantage
with respect to previous combined indices. For instance,
the unified dosimetry index (UDI) [25] makes use of four
dosimetric objectives of dose coverage, conformity, homo-
geneity, and dose gradient on the PTV. Although the UDI
provides a useful tool for ranking tentative plans, this
figure of merit relies in specific dose-volume constraints
instead to consider the overall dosimetric information
provided by the DVHs. Moreover, UDI does not directly
account for sparing of critical structures and does not
seem easy to use when multiple target dose coverage
objectives are specified. To consider a further example, a
histogram analysis in radiation therapy (HART) computa-
tional tool has been proposed in [26]. This software incor-
porates various physically and biologically based indices
for plan evaluation. Whereas HART is a complete and
Table 3 Scoring results for a patient diagnosed with a centrally
located Meningioma
IT IO IR DDI
Plan 1 0.832 0.821 0.948 0.867
Plan 2 0.923 0.789 0.934 0.882
Plan 3 0.934 0.776 0.918 0.876
IT , IO , IR and DDI scores for the set of three tentative plans simulated. The table
shows that Plan 1 (ATP) provides the highest sparing of OARs and RVR, while Plan 3
results in the best PTV coverage. However, the Plan 2 has the highest DDI score
suitable program to compare tentative plans, the results
are prone to the intrinsic limitations of the indices therein
considered, as reported in the ICRU reports [1–3].
We point out that the DDI is very sensitive to small dosi-
metric variations between tentative plans and distinctly
discriminates situations where DVHs look quite similar to
the naked eye. Furthermore, it may be also used to com-
pare tentative plans obtained from any TPS irrespective of
tumor type and location, and can be formulated for any
irradiation technique that provides DVHs. At the practi-
cal level, computing the DDI is straightforward, and that
decision-support system can be easily displayed on TPS
simultaneously to the visualization of the corresponding
DVHs. In addition, it may readily provide the separate val-
ues IT , IO and IR, as well as those for each single OAR,
which could be a useful complement to the DVH analysis.
Although the DDI can be used to globally assess the
quality of any treatment plan, its main practical interest
could be to compare tentative plans for a same patient. In
fact, depending on diverse factors as tumor malignancy
and location, curative or palliative purposes or overall
patient’s medical history, a dosimetric plan can have a
lower DDI score compared to other treatment plans for
different patients, and yet be the best possible choice
that satisfies concrete clinical requirements and treatment
goals in that particular case. On the other hand, for a given
patient different planners may well pursue different, and
occasionally conflicting, goals. For instance, dose coverage
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and conformity on the PTV may be given highest priority
in some cases, while palliative considerations may require
of minimal damage to OARs and the RVR in others. DDI is
not designed to change such priorities, but rather to help
clinicians to precisely assess the consequences of their
choices during treatment planning.
To give an idea of what DDI can accomplish, we have
presented a retrospective study, corresponding to fifty
patients treated at HUPH of centrally and peripherally
located benign and malignant brain tumors. In each case,
three tentative plans were simulated and recorded, out
of which one was eventually delivered to the patient. We
then compared the applied treatment plan (ATP) with
that which provides the highest DDI score (DDIP). We
observed that, under the assumption that PTV covering
and OARs and RVRs sparing are equally important, ATP
and DDIP coincided in 32 of the 50 cases. Discrepan-
cies between ATP and DDIP in the remaining 18 cases
may well result from different clinical priorities being
attributed to critical structures during planning. In fact,
in those cases ATP and DDIP also coincide, provided
that different orders of priorities (for instance, deeming
OARs sparing as the most important goal) are established
instead.
We finally remark on the modular character of the
quantitative index provided. In particular, DDI can be
combined with multi-parameter optimization algorithms
and included in objective functions during radiotherapy
planning processes. In fact, considerable attention is being
paid to the design of optimization methods to obtain
dose distributions satisfying specific criteria as high tumor
coverage and low radiation dose deposition on OARs
[3, 38–40]. However, no method has been found as yet
to computationally find a plan that satisfies current clin-
ical and logistical requirements in an optimal way. We
expect that implementing the DDI decision-support sys-
tem in current TPS would improve reliability standards,
by precisely quantifying the impact of planner subjectivity
in assessing and selecting radiotherapy treatment plans.
Conclusions
In this work a decision-support system has been devel-
oped to compare and evaluate different tentative plans
during radiotherapy treatment planning. The proposed
DDI is a straightforward and non-subjective system to
assess and compare competing tentative plans. The DDI
takes into account the overall dosimetric information
provided by DVHs and not only that given by selected
dose-volume constraints. Moreover, DDI can be easily
computed irrespective of the TPS in clinical use, tumor
type and localization, and irradiation technique. This
decision-support tool is not meant to be a replacement
for planners’ clinical decisions. Instead, it is intended
to provide clinical personnel with a precise quantitative
assessment of the impact of dosimetric changes over any
starting tentative plan that they might consider.
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